{"id":"temozolomide-plus-cisplatin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Temozolomide and cisplatin are both used in chemotherapy to treat various types of cancer. They work by targeting rapidly dividing cancer cells and inhibiting their growth. Temozolomide is particularly effective against glioblastoma, while cisplatin is used to treat a range of cancers, including lung, bladder, and testicular cancer.","oneSentence":"Temozolomide is an alkylating agent that works by interfering with DNA replication, while cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:04.250Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma"},{"name":"Malignant glioma"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT04457284","phase":"PHASE2","title":"Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-18","conditions":"Colorectal Adenocarcinoma","enrollment":18},{"nctId":"NCT07310784","phase":"PHASE2","title":"A Phase II Trial of LM103 in Advanced Melanoma","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2025-12-16","conditions":"Advanced Melanoma","enrollment":92},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT07400302","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2026-02-01","conditions":"Mucosal Melanoma, PD-L1 Positive","enrollment":220},{"nctId":"NCT06105619","phase":"PHASE2, PHASE3","title":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2018-10-08","conditions":"Glioblastoma","enrollment":84},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT02595424","phase":"PHASE2","title":"Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-04-06","conditions":"Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma","enrollment":67},{"nctId":"NCT06703398","phase":"PHASE2","title":"A Study of GC101 TIL in Advanced Melanoma","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2024-12-20","conditions":"Melanoma","enrollment":98},{"nctId":"NCT07141771","phase":"PHASE1, PHASE2","title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"SCLC, Extensive Stage","enrollment":100},{"nctId":"NCT07138001","phase":"PHASE2","title":"Phase 2 Clinical Trial of KH617","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","startDate":"2025-08","conditions":"Recurrent Glioblastoma","enrollment":60},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06186440","phase":"PHASE1, PHASE2","title":"Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2024-01-01","conditions":"Glioblastoma Multiforme of Brain","enrollment":60},{"nctId":"NCT06041724","phase":"PHASE2","title":"Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-09-18","conditions":"Advanced Mucosal Melanoma","enrollment":46},{"nctId":"NCT05694416","phase":"PHASE2","title":"Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2023-02-01","conditions":"MGMT-Unmethylated Glioblastoma","enrollment":60},{"nctId":"NCT04851834","phase":"PHASE1, PHASE2","title":"NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma","status":"TERMINATED","sponsor":"Xennials Therapeutics Australia Pty Ltd","startDate":"2021-08-25","conditions":"Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma","enrollment":12},{"nctId":"NCT05609162","phase":"","title":"Treatments for Brain Metastases With Poor Prognostic Factors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-12-15","conditions":"Brain Metastases","enrollment":2000},{"nctId":"NCT05647954","phase":"PHASE3","title":"A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-31","conditions":"Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms","enrollment":350},{"nctId":"NCT04796454","phase":"PHASE2","title":"Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2022-05","conditions":"Platinum-Sensitive Biliary Tract Cancer","enrollment":""},{"nctId":"NCT04462965","phase":"PHASE2","title":"Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-05-30","conditions":"Mucosal Melanoma","enrollment":294},{"nctId":"NCT00505635","phase":"PHASE2","title":"Biochemotherapy With Temozolomide for Metastatic Melanoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-03","conditions":"Melanoma","enrollment":5},{"nctId":"NCT01196416","phase":"PHASE1, PHASE2","title":"Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08","conditions":"Recurrent Melanoma, Stage IV Skin Melanoma","enrollment":14},{"nctId":"NCT01014767","phase":"PHASE3","title":"Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2009-11","conditions":"Brain Cancer, Choroid Plexus Tumors","enrollment":27},{"nctId":"NCT01284335","phase":"PHASE1","title":"A Safety Study in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2008-07","conditions":"Advanced Solid Tumors","enrollment":234},{"nctId":"NCT02263105","phase":"PHASE2","title":"Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2014-10","conditions":"High-grade Gliomas","enrollment":67},{"nctId":"NCT03435302","phase":"PHASE3","title":"HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2014-02","conditions":"Melanoma","enrollment":204},{"nctId":"NCT01260103","phase":"PHASE3","title":"Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma","status":"WITHDRAWN","sponsor":"Burzynski Research Institute","startDate":"2011-12","conditions":"Optic Nerve Glioma","enrollment":""},{"nctId":"NCT01409174","phase":"PHASE1","title":"IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02","conditions":"Melanoma","enrollment":19},{"nctId":"NCT02772107","phase":"PHASE2, PHASE3","title":"Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-12","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":132},{"nctId":"NCT00673361","phase":"PHASE2","title":"Pilot Trial of \"Chemo-Switch\" Regimen to Treat Advanced Melanoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-03","conditions":"Melanoma","enrollment":9},{"nctId":"NCT00084838","phase":"PHASE2","title":"Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2003-02","conditions":"Central Nervous System Tumor, Pediatric","enrollment":25},{"nctId":"NCT00003273","phase":"PHASE2","title":"Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"1997-11","conditions":"Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma","enrollment":""},{"nctId":"NCT00885534","phase":"PHASE2","title":"Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-04","conditions":"Melanoma, Skin Cancer","enrollment":7},{"nctId":"NCT00392886","phase":"PHASE3","title":"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors","status":"UNKNOWN","sponsor":"Children's Hospital Los Angeles","startDate":"2004-03","conditions":"Brain and Central Nervous System Tumors","enrollment":120},{"nctId":"NCT00360945","phase":"PHASE2","title":"Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2004-04","conditions":"Brain and Central Nervous System Tumors","enrollment":87},{"nctId":"NCT01743157","phase":"PHASE1, PHASE2","title":"Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2010-12","conditions":"Metastatic Melanoma","enrollment":24},{"nctId":"NCT00006043","phase":"PHASE2","title":"Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-02","conditions":"Ovarian Cancer, Testicular Germ Cell Tumor","enrollment":""},{"nctId":"NCT00970996","phase":"PHASE1","title":"Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-09","conditions":"Melanoma","enrollment":10},{"nctId":"NCT01670890","phase":"PHASE2","title":"Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-08","conditions":"Malignant Gliomas","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Temodal.","cisplatinum"],"phase":"phase_3","status":"active","brandName":"Temozolomide Plus Cisplatin","genericName":"Temozolomide Plus Cisplatin","companyName":"Peking University Cancer Hospital & Institute","companyId":"peking-university-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide is an alkylating agent that works by interfering with DNA replication, while cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cancer cell growth. Used for Glioblastoma, Malignant glioma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}